push pharmacy semaglutide Flex-Dose 4 mL Injectable 2.5 mg/mL What Is Semaglutide? A Medical

The global market for GLP-1 receptor agonists was valued at USD 53.46 billion in 2024 and is expected to grow to USD 156.71 billion by 2030 , reflecting a compound annual growth rate of 17.46% between 2025 and 2030

4 Clinical evidence In adults with obesity, 72 weeks of orforglipron treatment resulted in greater body-weight reductions than placebo, up to -11.2%, compared to -2.1% with placebo

It is important to acknowledge that primary OP is a multifactorial disorder, where bone loss and deterioration result from a confluence of factors such as aging, estrogen deficiency, reduced physical activity, nutritional deficits, immunosenescence, chronic low-grade inflammation, and genetic predisposition

These results concurred with recent studies [40, 51]